AU2190202A - Fused heteroaromatic glucokinase activators - Google Patents

Fused heteroaromatic glucokinase activators

Info

Publication number
AU2190202A
AU2190202A AU2190202A AU2190202A AU2190202A AU 2190202 A AU2190202 A AU 2190202A AU 2190202 A AU2190202 A AU 2190202A AU 2190202 A AU2190202 A AU 2190202A AU 2190202 A AU2190202 A AU 2190202A
Authority
AU
Australia
Prior art keywords
glucokinase activators
fused heteroaromatic
heteroaromatic glucokinase
fused
activators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2190202A
Other languages
English (en)
Inventor
Wendy Lea Corbett
Joseph Samuel Grimbsy
Nancy-Ellen Haynes
Robert Francis Kester
Paige Erin Mahaney
Ramakanth Sarabu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2190202A publication Critical patent/AU2190202A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2190202A 2000-12-06 2001-11-28 Fused heteroaromatic glucokinase activators Pending AU2190202A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25163700P 2000-12-06 2000-12-06
PCT/EP2001/013870 WO2002046173A1 (en) 2000-12-06 2001-11-28 Fused heteroaromatic glucokinase activators

Publications (1)

Publication Number Publication Date
AU2190202A true AU2190202A (en) 2002-06-18

Family

ID=22952803

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002221902A Ceased AU2002221902B2 (en) 2000-12-06 2001-11-28 Fused heteroaromatic glucokinase activators
AU2190202A Pending AU2190202A (en) 2000-12-06 2001-11-28 Fused heteroaromatic glucokinase activators

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2002221902A Ceased AU2002221902B2 (en) 2000-12-06 2001-11-28 Fused heteroaromatic glucokinase activators

Country Status (21)

Country Link
US (3) US6441184B1 (enExample)
EP (1) EP1341774B1 (enExample)
JP (1) JP4109111B2 (enExample)
KR (1) KR100545431B1 (enExample)
CN (1) CN1226294C (enExample)
AR (1) AR031627A1 (enExample)
AT (1) ATE316965T1 (enExample)
AU (2) AU2002221902B2 (enExample)
BR (1) BR0115999A (enExample)
CA (1) CA2429642C (enExample)
DE (1) DE60117059T2 (enExample)
DK (1) DK1341774T3 (enExample)
ES (1) ES2256340T3 (enExample)
GT (1) GT200100243A (enExample)
MX (1) MXPA03005119A (enExample)
PA (1) PA8534301A1 (enExample)
PE (1) PE20020753A1 (enExample)
PT (1) PT1341774E (enExample)
UY (1) UY27055A1 (enExample)
WO (1) WO2002046173A1 (enExample)
ZA (1) ZA200303748B (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
PL215132B1 (pl) * 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
US6775812B2 (en) * 2002-07-17 2004-08-10 Hewlett-Packard Development Company, L.P. Layout design process and system for providing bypass capacitance and compliant density in an integrated circuit
ATE374768T1 (de) 2002-10-03 2007-10-15 Hoffmann La Roche Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
CN101805358A (zh) * 2002-10-03 2010-08-18 诺瓦提斯公司 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑-2-基)酰胺或磺酰胺
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
DE602004012858T2 (de) * 2003-06-20 2009-05-14 F. Hoffmann-La Roche Ag 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
BRPI0507746A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
EP1718625A1 (en) * 2004-02-18 2006-11-08 AstraZeneca AB Compounds
WO2005095418A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
CA2561157A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
KR20060134179A (ko) * 2004-04-21 2006-12-27 프로시디온 리미티드 트리(사이클로) 치환된 아미드 화합물
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
CN101035767A (zh) 2004-08-12 2007-09-12 普洛希典有限公司 被取代的苯乙酰胺及其作为葡糖激酶激活剂的用途
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US7700640B2 (en) 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
CA2586056C (en) * 2004-11-02 2012-03-13 Banyu Pharmaceutical Co., Ltd. Aryloxy-substituted benzimidazole derivative
DE102005012872A1 (de) * 2005-03-19 2006-09-28 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2006125958A1 (en) * 2005-05-24 2006-11-30 Astrazeneca Ab 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
WO2007007040A1 (en) * 2005-07-09 2007-01-18 Astrazeneca Ab 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP1902052B1 (en) * 2005-07-09 2012-11-28 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
AU2006267338B2 (en) * 2005-07-13 2012-08-16 Msd K.K. Heterocycle-substituted benzimidazole derivative
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
AT503354B1 (de) * 2006-02-22 2008-07-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von 3,4-disubstituierten phenylessigsäuren, sowie neue zwischenverbindungen
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
EP2261216A3 (en) 2006-07-24 2011-12-14 F. Hoffmann-La Roche AG Pyrazoles as glucokinase activators
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) * 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
EP2121666A1 (en) * 2006-12-21 2009-11-25 AstraZeneca AB Novel crystalline compound useful as glk activator
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2116533B1 (en) 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
KR20100113518A (ko) * 2008-01-18 2010-10-21 아스텔라스세이야쿠 가부시키가이샤 페닐아세트아미드 유도체
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
NZ588462A (en) 2008-04-28 2012-07-27 Kyorin Seiyaku Kk Cyclopentylacrylic acid amide derivative
WO2010015849A2 (en) 2008-08-04 2010-02-11 Astrazeneca Ab Therapeutic agents 414
ES2610882T3 (es) * 2008-08-19 2017-05-03 Janssen Pharmaceutica, N.V. Antagonistas del receptor al mentol frío
GEP20135793B (en) * 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
ES2427279T3 (es) 2009-03-11 2013-10-29 Pfizer Inc. Derivados de benzofuranilo usados como inhibidores de glucocinasa
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
ES2624780T3 (es) 2010-03-31 2017-07-17 The Scripps Research Institute Reprogramación de células
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103764672A (zh) 2011-03-01 2014-04-30 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
ES2489297B1 (es) 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
ES2901114T3 (es) 2014-08-29 2022-03-21 Tes Pharma S R L Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
EP3294713B1 (en) 2015-05-15 2021-02-17 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ror gamma modulators
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
IL283182B2 (en) 2018-11-20 2025-10-01 Tes Pharma S R L Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
AU2021289309A1 (en) 2020-06-08 2023-01-19 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840550A (en) * 1971-05-24 1974-10-08 Ciba Geigy Corp Certain 6-isothiocyanobenzothiazoles
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
TR200102805T2 (tr) * 1999-03-29 2002-04-22 F.Hoffmann-La Roche Ag Glikokinaz aktivatörleri

Also Published As

Publication number Publication date
JP2004517087A (ja) 2004-06-10
US6448399B1 (en) 2002-09-10
AU2002221902B2 (en) 2006-11-23
AR031627A1 (es) 2003-09-24
PE20020753A1 (es) 2002-08-27
US20020103241A1 (en) 2002-08-01
CN1476438A (zh) 2004-02-18
US20020107396A1 (en) 2002-08-08
DE60117059D1 (de) 2006-04-13
DK1341774T3 (da) 2006-06-12
DE60117059T2 (de) 2006-10-26
ES2256340T3 (es) 2006-07-16
ZA200303748B (en) 2004-08-16
CN1226294C (zh) 2005-11-09
BR0115999A (pt) 2003-09-30
UY27055A1 (es) 2002-07-31
EP1341774A1 (en) 2003-09-10
KR20030068555A (ko) 2003-08-21
US6441184B1 (en) 2002-08-27
US20020103199A1 (en) 2002-08-01
ATE316965T1 (de) 2006-02-15
PA8534301A1 (es) 2002-08-26
WO2002046173A1 (en) 2002-06-13
PT1341774E (pt) 2006-05-31
US6545155B2 (en) 2003-04-08
EP1341774B1 (en) 2006-02-01
CA2429642A1 (en) 2002-06-13
CA2429642C (en) 2007-11-20
GT200100243A (es) 2002-06-04
JP4109111B2 (ja) 2008-07-02
MXPA03005119A (es) 2004-10-15
KR100545431B1 (ko) 2006-01-24

Similar Documents

Publication Publication Date Title
AU2190202A (en) Fused heteroaromatic glucokinase activators
AU5227001A (en) Hydantoin-containing glucokinase activators
EG23870A (en) Glucokinase activators
IL145322A0 (en) Glucokinase activators
AU6591401A (en) Para-amine substituted phenylamide glucokinase activators
AU7049401A (en) Alkynyl phenyl heteroaromatic glucokinase activators
AU8399801A (en) Tetrazolyl-phenyl acetamide glucokinase activators
DK1242397T3 (da) Trans-olefiniske glucokinaseaktivatorer
AU8520501A (en) Selected fused pyrrolocarbazoles
SI1669068T1 (sl) Spojine, ki učinkujejo na glukokinazo
IL147108A0 (en) Substituted heterocycle fused gamma-carbolines
AU6931701A (en) Pyrimidine derivatives
ZA200110272B (en) Multifunctional absorbent article.
PL365787A1 (en) Heterocyclic compounds, their production and use
AU1041802A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
AU9282601A (en) Osteogenic fusion devices
IL155705A0 (en) Pyrimidine derivatives
AU1392902A (en) Bicyclic heteroaromatic compounds
MXPA03001951A (es) Pirroliminas y pirazoliminas fusionadas substituidas.
GB0005547D0 (en) Multi-role pushchair
AU2009802A (en) Modulating angiogenesis
GB0020556D0 (en) Fused pyrazole derivatives
GB0008322D0 (en) Stroller
DK1282612T3 (da) Heteroaromatiske alkylphenyl-glucokinaseaktivatorer
TW479631U (en) Stroller